Clinical Trial Update: Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults. [Phase 3]

View source ↗

Summary

Pfizer's Phase 3 study evaluating the RSVpreF vaccine for efficacy, immunogenicity, and safety in adults with lower respiratory tract illness is active but not …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lower Respiratory Tract Infection
• Respiratory Syncytial Virus Infection

Drugs mentioned

• RSVpreF

Snippet

Sponsor: Pfizer | Conditions: Lower Respiratory Tract Illness | Phase 3 | Status: ACTIVE_NOT_RECRUITING